Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 15;8(10):745-750.
doi: 10.4251/wjgo.v8.i10.745.

Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature

Marwan Ghosn  1 , Hampig Raphael Kourie  1 , Elie El Rassy  1 , Fady Ghassan Haddad  1 , Colette Hanna  1 , Fadi El Karak  1 , Dolly Nasr  1
Affiliations
Review

Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature

Marwan Ghosn et al. World J Gastrointest Oncol. .

Abstract

Ampullary carcinoma (AC) is a rare gastrointestinal tumor without clear treatment recommendations. The management of this tumor is usually extrapolated from the treatment of pancreatic, biliary duct and intestinal cancers. Few papers have studied the AC as an independent entity and yet succombs to several limitations. These studies were retrospective single institutional experiences with limited sample sizes recruited over a long period of time. Unlike metastatic ACs where chemotherapy is the only recommended option, localized AC once excised may be approached by either chemotherapy alone or concomitant chemoradiation therapy. In this review, we report the overall survival and recurrence factors of more than 1000 patients from all the studies treating exclusively ACs. We also review the medical treatment of this tumor and conclude to the necessity of multi-institutional randomized controlled studies for AC exclusively.

Keywords: Ampullary cancer; Novel therapies; Prognostic factors; Review; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: To the best of our knowledge, no conflict of interest exists.

Figures

Figure 1
Figure 1
Concurrent American and European approach for the treatment of localized ampullary carcinoma[35]. 5-FU: 5-fluorouracil.
See this image and copyright information in PMC

References

    1. O’Connell JB, Maggard MA, Manunga J, Tomlinson JS, Reber HA, Ko CY, Hines OJ. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008;15:1820–1827. - PubMed
    1. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol. 2009;100:598–605. - PubMed
    1. Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, Pinese M, Humphris JL, Jones MD, Toon C, et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol. 2013;31:1348–1356. - PubMed
    1. Morris-Stiff G, Alabraba E, Tan YM, Shapey I, Bhati C, Tanniere P, Mayer D, Buckels J, Bramhall S, Mirza DF. Assessment of survival advantage in ampullary carcinoma in relation to tumour biology and morphology. Eur J Surg Oncol. 2009;35:746–750. - PubMed
    1. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology. [accessed 2014 Apr 1] Available from: http: //www.nccn.org/professionals/physician_gls/f_guidelines.asp.

LinkOut - more resources